NCT04050761Completed
A Study of Nivolumab in Patients With Head and Neck Cancer.
A French Prospective, Non-interventional Research ( NIR) of Nivolumab in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After a Platinum-based Therapy
Source: ClinicalTrials.gov · Last updated 2 Jul 2025
Brief summary (registry, in English)
A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 502 (actual)
- First submitted
- 2 Aug 2019
- Start date
- Jun 2019
- Primary completion date
- Jul 2024
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Head and neck cancer
- NCT number
- NCT04050761
What you commit to
- Study type: Observational
- Participants enrolled: 502
- From Jun 2019 to the primary completion date, Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients previously treated with Nivolumab, Ipilimumab, or any other antibody or drug specifically targeting T-Cell Co stimulation or immune Checkpoint pathway.
Other
- Patients currently included in an interventional clinical trial for their SCCHN.
- Other protocol defined inclusion/exclusion criteria could apply
Who the study is looking for
- Diagnosis of Squamous Cell Carcinoma Head and Neck (SCCHN) patients progressing on or after platinum-based therapy.
- Diagnosis of SCCHN has been confirmed by histology or cytology (either at initial diagnosis or any time later during the course of the disease)
- Treatment decision to initiate a treatment with nivolumab for the first time for the treatment of SCCHN (according to the label approved in France) has already been taken
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.